What’s Next in CAR T Cell Therapy with Dr. Michel Sadelain
HTML-код
- Опубликовано: 28 июл 2024
- CAR T cell therapy uses a patients’ immune cells equipped with chimeric antigen receptors (CARs) to enhance their ability to target and eliminate cancer cells. #CRIwebinar #CARTcell www.cancerresearch.org/webinars
In this webinar for patients and caregivers, Michel Sadelain, M.D., Ph.D., of Memorial Sloan Kettering Cancer Center (MSKCC), discusses this CAR T cell immunotherapy approach that he helped pioneer.
Our immune system possesses incredible cancer-fighting capabilities, but sometimes it benefits from a little boost. Imagine that we could take immune cells from patients, enhance them outside the body, and then infuse them back into patients where they can seek out and eliminate cancer cells. No longer the stuff of science fiction, one of these adoptive cell therapy approaches-known as CAR T cell therapy-has already achieved success in the clinic and appears to have a promising future in cancer treatment.
By taking patients’ own immune cells and equipping them with chimeric antigen receptors (CARs) that enhance their ability to target and eliminate cancer cells, CAR T cells have already provided immense benefits for patients with leukemia and lymphoma, and now are being explored in solid tumors, too. In particular, Sadelain discusses how these powerful “living drugs” are created, how they work once in the body, and how recent discoveries and advances are enabling scientists to improve their effectiveness for more cancer patients.
Dr. Michel Sadelain serves as the director of the Center for Cell Engineering, the director of the Gene Transfer and Gene Expression Laboratory, and the Stephen and Barbara Friedman Chair. In addition, Sadelain is a member of the CRI Clinical Accelerator leadership, a former member of the CRI-SU2C Dream Team, and the recipient of the 2012 William B. Coley Award for Distinguished Research in Tumor Immunology.
Sadelain’s work provided the foundation upon which the first two FDA-approved CAR T cell immunotherapies were developed. After demonstrating the effectiveness of CD19-targeting CAR T cells in mice, this strategy was applied in the clinic, where it’s provided great benefits so far for both adult and pediatric patients. More recently, Dr. Sadelain has continued to advance our understanding of CAR T cells and reveal important insights that are being used to improve their activity. These include the development of novel strategies to overcome the resistance that can occur as well as efforts aimed at increasing CAR T cell survival and persistence in patients so that they can provide long-term protection.
The "Cancer Immunotherapy and You" webinar series is produced by the Cancer Research Institute and is hosted by our science writer, Arthur Brodsky, Ph.D. The 2019 series is made possible with generous support from Bristol-Myers Squibb, Cellectis and Celgene. Browse our Cancer Immunotherapy and You Webinar Series playlist on RUclips or visit the Webinars page on our website to see other webinars in this series. www.cancerresearch.org/events...
The "Cancer Immunotherapy and You" webinar series is part of the Cancer Research Institute's Answer to Cancer Patient Education Program. Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. www.cancerresearch.org
Thankyou for posting this info . My son has acute lymphoblastic t cell leukaemia .
Outstanding
That was exceptionally well explained.
Great talk .
I am writing my cover letter to join a research group that works in Immunotherapy! Your work is inspiring and bringing hope :)
Ahmed El-Molla I will give up if I cannot find a new team to join this year. Very hard due to my age.
@@penguinlieo4723 I have been applying for a lot of time as well, and it's really hard indeed. But I think it's even harder when you start working. So don't give up man. Not now and not later when you are accepted in a good place inshaAllah :)
Thank you very much for preparing this great webinar which could help me out to appreciate more precisely. I am very interested in immunotherapy and I also am going to present my project in this significant field. As you have mentioned TME is able to produce molecular and cellular barriers for decreasing CAR T cells’ efficiency and preventing from CAR T cells’ entrance in solid tumors.
Many thanks once again.
Wow, thank you for the feedback, Parvin :)
Great webinair guys!
Dear Colleagues. Thank you for very informative and helpful information. I am agree that this like therapy will be useful in cancer treatment.
How I can apply for investigation in the this field. I have some ideas for fighting against cancer.
Have any clinical trials been conducted with CAR-T cells targeting solid tumours such as Osteosarcoma? My son was diagnosed with Osteosarcoma in June 2018, and since then he has had limb salvage surgery & multiple rounds of aggressive pre- and post-surgery chemotherapy. Sadly he has had a few relapses since his treatment finished earlier this year, and his recent PET scan in November 2019 has detected multiple tumours throughout his body, including in his lungs. He is now back on chemotherapy, and we are now resigned to the fact that the chemotherapy is just a short term solution. We have read up on CAR-T cell immunotherapy, which seems to be quite effective, and would be very grateful if you could advise whether this may be an option in treating our son's diagnosis. If not, are you aware of any other treatments available? Thanking you very much in advance.
Hi Ritesh. You can find current immunotherapy treatment options and clinical trials on our website here:
www.cancerresearch.org/immunotherapy/cancer-types/childhood-cancer
www.cancerresearch.org/immunotherapy/cancer-types/sarcoma
Can CAR T-cell therapy be used to treat thalassemia and sickle cell anemia?
14:27 CAR-T cells are capable of multiplying when activated. Are they capable of uncontrolled growth?
Hi Pankti, to learn more about CAR T cell therapy: www.cancerresearch.org/immunotherapy/treatment-types/adoptive-cell-therapy#cart
When can we expect car t for liver, pancreas, stomach and colon cancer?
There are adoptive cell therapies in clinical trials for all those cancers. Learn more:
liver cancer - www.cancerresearch.org/immunotherapy/cancer-types/liver-cancer
pancreatic cancer - www.cancerresearch.org/immunotherapy/cancer-types/pancreatic-cancer
stomach cancer - www.cancerresearch.org/immunotherapy/cancer-types/stomach-cancer
colorectal cancer - www.cancerresearch.org/immunotherapy/cancer-types/colorectal-cancer
many ongoing trials, but its very hard to do car t on solid tumor due to many microenvironment limitations.
@@zhexu1727 The answer to the micoenvironment situation is to destroy it. High dose IV vitamin C and even a healthy diet largley consisting of vegetables, does a great job at unraveling the microenvironment. Chemotherapy only kills the tumors and by doing that, it creates a debris and collection of dead cells which adds onto the cancer microenvironment, highly acidic and anerobic area.